Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Serum estrogen and tumor-positive estrogen receptor-alpha are strong prognostic classifiers of non-small-cell lung cancer survival in both men and women.

Olivo-Marston SE, Mechanic LE, Mollerup S, Bowman ED, Remaley AT, Forman MR, Skaug V, Zheng YL, Haugen A, Harris CC.

Carcinogenesis. 2010 Oct;31(10):1778-86. doi: 10.1093/carcin/bgq156. Epub 2010 Aug 20.

2.

Serum estrogen receptor beta mediated bioactivity correlates with poor outcome in lung cancer patients.

Lim VW, Lim WY, Zhang Z, Li J, Gong Y, Seow A, Yong EL.

Lung Cancer. 2014 Aug;85(2):293-8. doi: 10.1016/j.lungcan.2014.05.019. Epub 2014 Jun 4.

PMID:
24951317
3.

The validation of estrogen receptor 1 mRNA expression as a predictor of outcome in patients with metastatic non-small cell lung cancer.

Atmaca A, Al-Batran SE, Wirtz RM, Werner D, Zirlik S, Wiest G, Eschbach C, Claas S, Hartmann A, Ficker JH, Jäger E, Brueckl WM.

Int J Cancer. 2014 May 15;134(10):2314-21. doi: 10.1002/ijc.28571. Epub 2013 Nov 14.

4.

Lung cancer survival and functional polymorphisms in MBL2, an innate-immunity gene.

Pine SR, Mechanic LE, Ambs S, Bowman ED, Chanock SJ, Loffredo C, Shields PG, Harris CC.

J Natl Cancer Inst. 2007 Sep 19;99(18):1401-9. Epub 2007 Sep 11.

PMID:
17848669
5.

Prognostic relevance of estrogen receptor α, β and aromatase expression in non-small cell lung cancer.

Skjefstad K, Grindstad T, Khanehkenari MR, Richardsen E, Donnem T, Kilvaer T, Andersen S, Bremnes RM, Busund LT, Al-Saad S.

Steroids. 2016 Sep;113:5-13. doi: 10.1016/j.steroids.2016.05.008. Epub 2016 May 24.

PMID:
27234503
6.

Gender difference in estrogen receptor alpha promoter hypermethylation and its prognostic value in non-small cell lung cancer.

Lai JC, Cheng YW, Chiou HL, Wu MF, Chen CY, Lee H.

Int J Cancer. 2005 Dec 20;117(6):974-80.

7.

Serum concentrations of cytokines and lung cancer survival in African Americans and Caucasians.

Enewold L, Mechanic LE, Bowman ED, Zheng YL, Yu Z, Trivers G, Alberg AJ, Harris CC.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):215-22. doi: 10.1158/1055-9965.EPI-08-0705.

8.

Prognostic significance of survivin polymorphisms on non-small cell lung cancer survival.

Dai J, Jin G, Dong J, Chen Y, Xu L, Hu Z, Shen H.

J Thorac Oncol. 2010 Nov;5(11):1748-54. doi: 10.1097/JTO.0b013e3181f18cb9.

10.

Estrogen receptor alpha and beta are prognostic factors in non-small cell lung cancer.

Kawai H, Ishii A, Washiya K, Konno T, Kon H, Yamaya C, Ono I, Minamiya Y, Ogawa J.

Clin Cancer Res. 2005 Jul 15;11(14):5084-9.

11.

Tobacco and estrogen metabolic polymorphisms and risk of non-small cell lung cancer in women.

Cote ML, Yoo W, Wenzlaff AS, Prysak GM, Santer SK, Claeys GB, Van Dyke AL, Land SJ, Schwartz AG.

Carcinogenesis. 2009 Apr;30(4):626-35. doi: 10.1093/carcin/bgp033. Epub 2009 Jan 27.

12.

Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.

Wu X, Ye Y, Rosell R, Amos CI, Stewart DJ, Hildebrandt MA, Roth JA, Minna JD, Gu J, Lin J, Buch SC, Nukui T, Ramirez Serrano JL, Taron M, Cassidy A, Lu C, Chang JY, Lippman SM, Hong WK, Spitz MR, Romkes M, Yang P.

J Natl Cancer Inst. 2011 May 18;103(10):817-25. doi: 10.1093/jnci/djr075. Epub 2011 Apr 11.

13.

Oestrogen receptor beta over expression in males with non-small cell lung cancer is associated with better survival.

Skov BG, Fischer BM, Pappot H.

Lung Cancer. 2008 Jan;59(1):88-94. Epub 2007 Oct 1.

PMID:
17905466
14.

Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer.

Glubb DM, Paré-Brunet L, Jantus-Lewintre E, Jiang C, Crona D, Etheridge AS, Mirza O, Zhang W, Seiser EL, Rzyman W, Jassem J, Auman T, Hirsch FR, Owzar K, Camps C, Dziadziuszko R, Innocenti F.

J Thorac Oncol. 2015 Jul;10(7):1067-75. doi: 10.1097/JTO.0000000000000549.

15.

The prognostic impact of tumor cell expression of estrogen receptor-α, progesterone receptor, and androgen receptor in patients irradiated for nonsmall cell lung cancer.

Rades D, Setter C, Dahl O, Schild SE, Noack F.

Cancer. 2012 Jan 1;118(1):157-63. doi: 10.1002/cncr.26282. Epub 2011 Jun 28.

16.

Association of polymorphisms at HORMAD2 and prognosis in advanced non-small-cell lung cancer patients.

Zhang K, Tang S, Cao S, Hu L, Pan Y, Ma H, Guo X, Wu S, Shen H, Hu Z.

Cancer Epidemiol. 2014 Aug;38(4):414-8. doi: 10.1016/j.canep.2014.03.013. Epub 2014 May 3.

PMID:
24797335
17.

High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor α-positive breast cancer patients.

Asano T, Sato S, Yoshimoto N, Endo Y, Hato Y, Dong Y, Takahashi S, Fujii Y, Toyama T.

Jpn J Clin Oncol. 2014 Oct;44(10):889-97. doi: 10.1093/jjco/hyu113. Epub 2014 Aug 27.

PMID:
25163465
18.

Reproductive factors, hormone use, estrogen receptor expression and risk of non small-cell lung cancer in women.

Schwartz AG, Wenzlaff AS, Prysak GM, Murphy V, Cote ML, Brooks SC, Skafar DF, Lonardo F.

J Clin Oncol. 2007 Dec 20;25(36):5785-92.

PMID:
18089876
19.

VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.

Heist RS, Zhai R, Liu G, Zhou W, Lin X, Su L, Asomaning K, Lynch TJ, Wain JC, Christiani DC.

J Clin Oncol. 2008 Feb 20;26(6):856-62. doi: 10.1200/JCO.2007.13.5947.

PMID:
18281657
20.

Prognostic role of serum p53 antibodies in lung cancer.

Mattioni M, Soddu S, Prodosmo A, Visca P, Conti S, Alessandrini G, Facciolo F, Strigari L.

BMC Cancer. 2015 Mar 18;15:148. doi: 10.1186/s12885-015-1174-4.

Supplemental Content

Support Center